[Use of thyrocalcitonin by the trans-dentinopulpal route as a means of stabilizing and preventing rejection of human teeth homografts. Results and radiological changes (author's transl)].
Clinical and radiological results of an antirejection therapy based on the local action of a thyroid hormone, thyrocalcitonin, were studied. A double action was noted as it may stop the rhyzalase, and, more particularly, it reestablishes normal alveolodental relationships. Immunological factors are discussed. The therapeutic mode of action is emphasized as being a new method of local treatment.
D002116:Calcitonin / Q000008:administration & dosage* / Q000494:pharmacology; D003782:Dental Pulp; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000187:drug effects*; D006801:Humans; D011861:Radiography, Dental; D012391:Root Resorption / Q000188:drug therapy; D014070:Tooth / Q000637:transplantation*; D014184:Transplantation, Homologous
D002116:Calcitonin
Essai d'une thérapeutique anti-rejet dans le cas d'une homogreffe de dent humaine: la thyrocalcitonine par voie trans-dentino-pulpaire. Résultats et évolution radiologique; une méthode de stabilisation du rejet? (author's transl)]